Vertex Pharmaceuticals (VRTX): financials, SEC filings and peers

Vertex Pharmaceuticals (VRTX) is a biotechnology company in the Health Care sector of the S&P 500, headquartered in Boston, Massachusetts.

It was founded in 1989 and joined the S&P 500 on September 23, 2013.

Its fiscal year ends in December, and its shares trade on the Nasdaq.

In its SEC filings it is classified as “Pharmaceutical Preparations”.

Vertex Pharmaceuticals at a glance

Revenue (12 months): $13.0B
Revenue growth: +10.5%
Operating margin: 33.2%
Net income (12 months): $4.0B
Free cash flow (12 months): $3.2B
Cash: $5.0B
Debt: $4.5B
Diluted EPS (12 months): $15.53

Twelve months to September 30, 2026, from the 10-Q filed November 3, 2026.

Latest twelve months

Over the twelve months to September 30, 2026, Vertex Pharmaceuticals reported revenue of $13.0 billion, up 10.5% from a year earlier.

Its operating margin was 33.2%: for every $100 of sales, about $33 was left as operating profit.

Net income was $4.0 billion (30.7% of revenue), 8.2% higher than a year earlier.

Operating cash flow was $3.7 billion and capital spending $492 million, leaving free cash flow of $3.2 billion (24.7% of revenue).

At the end of the period it held $5.0 billion in cash and $4.5 billion in debt, a net cash position of $483 million.

Five-year trend

Revenue went from $6.2 billion in fiscal 2020 to $12.0 billion in fiscal 2025, about 14.1% a year.
Revenue has grown for 5 fiscal years in a row.
Operating margin narrowed from 46.0% to 34.8% over the same years.
Free cash flow was negative in 1 of the last 6 fiscal years.
Vertex Pharmaceuticals reported a net loss in 1 of the last 6 fiscal years.

Fiscal year	2021	2022	2023	2024	2025
Revenue	$7.6B	$8.9B	$9.9B	$11.0B	$12.0B
Revenue growth	22.1%	17.9%	10.5%	11.7%	8.9%
Operating margin	36.7%	48.2%	38.8%	-2.1%	34.8%
Net income	$2.3B	$3.3B	$3.6B	−$536M	$4.0B
Free cash flow	$2.4B	$3.9B	$3.3B	−$790M	$3.2B
Diluted EPS	$9.01	$12.82	$13.89	$-2.08	$15.32

Fiscal years as reported in Vertex Pharmaceuticals’s 10-K filings. Free cash flow is operating cash flow minus capital spending.

Recent SEC filings

10-Q filed November 3, 2026 — quarterly report
8-K filed November 2, 2026 — Earnings results
8-K filed October 20, 2026 — Executive or director change
8-K filed September 1, 2026 — Executive or director change
10-Q filed August 4, 2026 — quarterly report
8-K filed August 3, 2026 — Earnings results
8-K filed July 7, 2026 — Material agreement; Regulation FD disclosure
8-K filed May 13, 2026 — Executive or director change; Shareholder vote results

All Vertex Pharmaceuticals filings on SEC EDGAR

Companies like Vertex Pharmaceuticals

Other S&P 500 companies in Biotechnology:

More from Health Care

All 60 Health Care companies →

Questions about Vertex Pharmaceuticals

Is Vertex Pharmaceuticals's revenue growing?

Yes. Revenue for the twelve months to September 30, 2026 was $13.0 billion, up 10.5% from a year earlier, according to its SEC filings.

Is Vertex Pharmaceuticals profitable?

Yes. It earned $4.0 billion in net income over the twelve months to September 30, 2026, a net margin of 30.7%.

Does Vertex Pharmaceuticals have more cash or more debt?

At September 30, 2026 it had $5.0 billion in cash and $4.5 billion in debt, so more cash than debt.

When did Vertex Pharmaceuticals last file financial results?

Its latest quarterly report (10-Q) was filed with the SEC on November 3, 2026.

Which companies are similar to Vertex Pharmaceuticals?

In the S&P 500, Vertex Pharmaceuticals is grouped in Biotechnology within the Health Care sector. AbbVie (ABBV), Amgen (AMGN), Biogen (BIIB), Gilead Sciences (GILD), Incyte (INCY) are in the same group.

Understand the numbers

Source: Vertex Pharmaceuticals’s filings with the U.S. Securities and Exchange Commission (EDGAR), retrieved November 11, 2026. Figures are as reported by the company and may be restated. This page is for information only and is not financial advice.